Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 6c

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 9, 2021 7:30 AM EST

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.

Bipolar depression launch preparations are progressing well; sales force expansion is substantially complete.

Total revenues were $22.2 million for the third quarter of 2021, compared to $7.4 million for the same period in the prior year, representing an increase of approximately 200%.

CAPLYTA achieved net product revenues of $21.6 million for the third quarter of 2021. Third quarter CAPLYTA total prescriptions (TRx) increased 15% versus the previous quarter.

Patient enrollment... More